secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-11-05T22:50:37+00:00
Accession:  0001213900-26-116484
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tempest Therapeutics gets Nasdaq bid-price notice; TPST has until May 3, 2027 to top $1.00
--------------------------------------------------------------------------------

- Nasdaq Listing Qualifications Staff letter dated Nov. 4, 2026: TPST common stock closed below $1.00 for the last 30 consecutive business days, violating Rule 5550(a)(2).
- Company has 180 calendar days, until May 3, 2027, to regain compliance; requires a closing bid of at least $1.00 for a minimum of 10 consecutive business days.
- Notice has no immediate effect on the Nasdaq listing of TPST shares or on business operations, per the filing.
- If not cured by May 3, 2027, Tempest may qualify for a second 180-day period if it meets market-value and other Capital Market standards and signals a reverse split if needed.
- Company said it will actively monitor its closing bid price and evaluate options to resolve the deficiency; CEO Matthew Angel signed the filing Nov. 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000121390026116484/0001213900-26-116484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000121390026116484/ea0311157-8k_tempest.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-116484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer